Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam to Sell $125M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it will raise $125 million through the public sale of common stock.

The move comes as Alnylam stock is riding at around $19.90 a share, near a 52-week high of $21.38. It also follows the company's recent litigation settlement with one-time partner Tekmira Pharmaceuticals, which called for Alnylam to pay out $65 million to end the dispute (GSN 11/15/2012).

Alnylam said in a filing with the US Securities and Exchange Commission that it will use the proceeds of the offering for general corporate purposes, which may include research and development expenses, general and administrative expenses, and the potential acquisition of companies or technologies.

"Management will retain broad discretion over the allocation of net proceeds," Alnylam said in the filing.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.